


ClearSight System Technology Overview

How does it work?


Volume clamp method

- The essence is to dynamically provide equal pressures on either side of the wall of the artery by clamping the artery to a certain constant volume
- 1000 times each second the cuff pressure is adjusted to keep the diameter of the finger arteries constant
- Continuous recording of the cuff pressure results in a real-time finger pressure waveform¹




The Physiocal method – Physiological Calibration

- The Physiocal method is the real-time expert system that determines the proper arterial 'unloaded' volume, i.e. no pressure gradient across the arterial wall
- Automatic, periodic adjustments are essential to track the unloaded volume clamp setpoint when smooth muscle tone changes (e.g. during vasoconstriction)
- Calibration interval starts at 10 beats, but it increases to every 70 beats as stability increases
- Physiocal interval >30 beats is considered reliable²




Brachial pressure reconstruction

- Clinical standard for noninvasive BP is brachial level
- The ClearSight system reconstructs the brachial arterial pressure waveform from the finger arterial pressure waveform
- The reconstruction algorithm is based on a vast clinical database³



Cardiac output calculation

- Stroke volume is calculated by an algorithm based on an improved pulse contour method using:
 - The area under systolic portion of blood pressure curve (**Systolic Pressure-time Integral - SPI**)
 - A physiological model to calculate afterload individualized by age, gender, height and weight
- Cardiac output results from stroke volume times heart rate and is updated every beat⁴



References

- Peñáz J. Photoelectric measurement of blood pressure, volume and flow in the finger. 1973; Dresden 1973. p. 104
- Wesseling KH, Wit B, Hoeven GMA, Goudoever J, Settels JJ. Physiocal, calibrating finger vascular physiology for Finapres. Homeostasis. 1995;36:67–82.
- Gizdulich P, Prentza A, Wesseling KH. Models of brachial to finger pulse wave distortion and pressure decrement. Cardiovasc Res. 1997;33:698–705. doi: 10.1016/S0008-6363(97)00003-5
- Truijen J, van Lieshout JJ, Wesselink WA, Westerhof BE. Noninvasive continuous hemodynamic monitoring. J Clin Monit Comput. 2012 Jun 14.

Validation of monitoring blood pressure and cardiac output with non-invasive finger cuff technology versus traditional methods

Blood pressure validation studies

		BP can be measured reliably according to AAMI standard, bias <5 and SD < 8 mmHg	Bias ± SD
Vs. Noninvasive upper arm cuff			
Akkermans et al. – Hypertension in Pregnancy 2009 ⁶	33 pregnant patients	SYS 2.3±6.8 / DIA 0.8±6.3	
Eeftinck Schattenkerk et al. – Am J Hypertension 2009 ⁷	104 volunteers	SYS 4.3±9.3 / DIA -2.5±8.1	
Vs. Invasive radial line			
Martina et al. – Anesthesiology 2012 ⁸	50 cardiac surgery patients	MAP 2.2±6.4 mmHg	
Fischer et al. – Brit J Anesthesia 2012 ⁹	44 cardiac surgery patients	MAP -4.6±6.5 mmHg	
Martina et al. – ASAIO J 2010 ¹⁰	18 patients during CPB	MAP -1.3±6.5 mmHg	
Vos et al. – Brit J Anesthesia 2014 ¹¹	112 OR patients	MAP 2.0±9.0 mmHg	

Cardiac output validation studies

		Measurement of relative changes in CO performs comparably with invasive measurements	Percentage error
Vs. Noninvasive upper arm cuff			
Bubenek-Turconi et al – Anesthesia-Analgesia 2013 ¹²	28 cardiac surgery patients	38%	
Bogert et al – Anaesthesia 2010 ¹³	25 post CABG patients	30%	
Stover et al – BMC Anesthesiology 2009 ¹⁴	10 severely ill ICU patients	29%	
Vs. Transpulmonary thermodilution			
Broch et al – Anaesthesia 2012 ¹⁵	40 cardiac surgery patients	23% / 26%	
Hofhuizen et al. – J of Critical Care 2014 ¹⁶	20 post-cardiac patients	38.9%	
Vs. Trans-thoracic echo-Doppler			
van der Spoel et al. – J Clin Anesth 2012 ¹⁷	40 ASA 1-2 patients	39%	
Vs. Esophageal echo-Doppler			
Chen et al. J Clin Anesth 2012 ¹⁸	25 ASA 1-3 patients	37%	

References (continued)

5. Nowak RM, Sen A, Garcia AJ, Wilkie H, Yang JJ, Nowak MR, Moyer ML. Noninvasive continuous or intermittent blood pressure and heart rate patient monitoring in the ED. *Am J Emerg Med.* 2011;29(7):782-9.
6. Akkermans J, Diepeveen M, Ganzevoort W, van Montfrans GA, Westerhof BE, Wolf H. Continuous non-invasive blood pressure monitoring, a validation study of Nexfin in a pregnant population. *Hypertens Pregnancy.* 2009 May; 28(2):230-42. doi: 10.1080/10641950802601260
7. Eeftinck Schattenkerk DW, Van Lieshout JJ, Van den Meiracker AH, Wesseling KR, Blanc S, Wieling W, Van Montfrans GA, Settels JJ, Wesseling KH, Westerhof BE. Nexfin noninvasive continuous blood pressure validated against Riva-Rocci/Korotkoff. *Am J Hypertens.* 2009;22:378-83.
8. Martina JR, Westerhof BE, Van Goudoever J, de Beaumont EM, Truijen J, Kim YS, Immink RV, Jobsis DA, Hollmann MW, Lahpor JR, De Mol BA, Van Lieshout JJ. Noninvasive continuous arterial blood pressure monitoring with nexfin. *Anesthesiology.* 2012;116:1092-103.
9. Fischer MO, Avram R, Cârjaliu I, Massetti M, Gérard JL, Hanouz JL, Fellahi JL. Non-invasive continuous arterial pressure and cardiac index monitoring with Nexfin after cardiac surgery. *Br J Anaesth.* 2012 Oct;109(4):514-21
10. Martina JR, Westerhof BE, Van Goudoever J, De JN, Van Lieshout JJ, Lahpor JR, De Mol BA. Noninvasive blood pressure measurement by the Nexfin monitor during reduced arterial pulsatility: a feasibility study. *ASAIO J.* 2010;56:221-7.
11. Vos JJ, Poterman M, Mooyaart EA, Weening M, Struys MM, Scheeren TW, Kalmar AF. Comparison of continuous non-invasive finger arterial pressure monitoring with conventional intermittent automated arm arterial pressure measurement in patients under general anaesthesia. *Br J Anaesth.* 2014 Jul;113(1):67-74.
12. Bubenek-Turconi SI, Craciun M, Miclea I, Perel A. Noninvasive Continuous Cardiac Output by the Nexfin Before and After Preload-Modifying Maneuvers: A Comparison with Intermittent Thermodilution Cardiac Output. *Anesth Analg.* 2013 Aug;117(2):366-72.
13. Bogert LW, Wesseling KH, Schraa O, Van Lieshout Ej, De Mol BA, Van GJ, Westerhof BE, Van Lieshout JJ. Pulse contour cardiac output derived from non-invasive arterial pressure in cardiovascular disease. *Anaesthesia.* 2010;65:1119-25.
14. Stover JF, Stocker R, Lenherr R, Neff TA, Cottini SR, Zoller B, Béchir M. Noninvasive cardiac output and blood pressure monitoring cannot replace an invasive monitoring system in critically ill patients. *BMC Anesthesiol.* 2009 Oct 12;9:6. doi: 10.1186/1471-2253-9-6.
15. Broch O, Renner J, Gruenewald M, Meybohm P, Schoettler J, Caliebe A, Steinfath M, Malbrain M, Bein B. A comparison of the Nexfin and transcardiopulmonary thermodilution to estimate cardiac output during coronary artery surgery. *Anaesthesia.* 2012;67:377-83.
16. Hofhuizen C, Lansdorp B, van der Hoeven JG, Scheffer GJ, Lemson J. Validation of noninvasive pulse contour cardiac output using finger arterial pressure in cardiac surgery patients requiring fluid therapy. *Journal of Critical Care* 2014 Feb;29(1):161-5.
17. van der Spoel AG, Voogel AJ, Folkers A, Boer C, Bouwman RA. Comparison of noninvasive continuous arterial waveform analysis (Nexfin) with transthoracic Doppler echocardiography for monitoring of cardiac output. *J Clin Anesth.* 2012 Jun;24(4):304-9. doi: 10.1016/j.jclinane.2011.09.008.
18. Chen G, Meng L, Alexander B, Tran NP, Kain ZN, Cannesson M. Comparison of noninvasive cardiac output measurements using the Nexfin monitoring device and the esophageal Doppler. *J Clin Anesth.* 2012 Jun;24(4):275-83. doi: 10.1016/j.jclinane.2011.08.014.

For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

Edwards Lifesciences devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/ EEC bear the CE marking of conformity.

Edwards, Edwards Lifesciences, the stylized E logo, ClearSight, Nexfin and PhysioCal are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2021 Edwards Lifesciences Corporation. All rights reserved. PP-EU-1850 v1.0

Edwards Lifesciences • Route de L'Etraz 70, 1260 Nyon, Switzerland • edwards.com

